Chemomab shares surge 37.75% after-hours after announcing presentation at Oppenheimer Healthcare Conference.

Chemomab Therapeutics (Nasdaq: CMMB) surged 37.75% in after-hours trading following the announcement that CEO Dr. Adi Mor and senior management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The virtual event includes a corporate presentation webcast and one-on-one investor meetings, offering visibility into the company’s progress with nebokitug, its first-in-class CCL24-targeting therapy for fibro-inflammatory diseases. The news aligns with the stock’s upward movement, as the conference provides a platform to highlight clinical advancements, including positive Phase 2 data in primary sclerosing cholangitis and regulatory designations (Orphan Drug, Fast Track). The event likely boosted investor confidence by reinforcing the company’s pipeline potential and strategic momentum.